Patients with ALL or lymphoma who received the first FDA-approved CAR T-cell therapy, CD19-directed CARs, have had the most extensive characterization of the toxicities underlying CAR T-cell therapy to date [7]. Here, CD19 is linked to acute lymphoblastic leukemia.